TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05660486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Participants in this group will receive 2-3 drops of 100% pure Lavandula angustifolia essential oil applied to a surgical mask pre-procedure for aromatherapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group will receive 2-3 drops of water applied to a surgical mask pre-procedure.
Study: NCT06524206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Awareness, Courage and Love Intervention
Description: Derived from Functional Analytic Psychotherapy (FAP), the Awareness, Courage, and Love (ACL) Intervention brings the FAP principles to a broader population. In the ACL model, awareness is defined as engaging in mindful awareness of one's self (feelings, needs, values), other individuals, and the context in which interactions are taking place. Courage is defined as engaging in authentic, vulnerable self-disclosures (e.g. struggles, appreciation), and asking for what one wants and needs. Love is defined as providing empathically accurate responsiveness, including provision of safety, validation, and giving the other person what they have asked for when possible.
Study: NCT04157231

Intervention type: OTHER
Group type: OTHER
Intervention: Acute stroke care Intervention arm
Description: Training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. The aim of these sessions will be to educate stroke champions and other site staff on the management protocols. Available training resources will be accessed (including online materials) and simulation training will be used. New skills such as dysphagia assessment will be emphasized based on existing knowledge and competencies. After training, staff will have another assessment (Post-test) in order to determine whether they have been adequately trained and are able to adhere to the essential acute stroke care management plan. A standardised Power Point presentation and accompanying handouts will be made available for further use in the ward.~Refresher training will be provided monthly during the intervention.
Study: NCT05795244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: - Nivolumab 480 mg/every 4 weeks/IV infusion/6 cycles
Study: NCT04456569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geniculate Artery Embolization
Description: All patients within the embolization group will undergo unilateral angiography and embolization of the appropriate treatment limb geniculate arteries. For patients with bilateral disease the more clinically symptomatic side will be chosen as the treatment/control knee.
Study: NCT05074485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: intravenous injection of 100 milligrams anakinra

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: intravenous injection of 100 milligrams anakinra

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous injection of 1 milliliter normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous injection of 1 milliliter normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nociceptive pain challenge
Description: The experimental, standardized, nociceptive pain challenge will induce a moderate level of sustained pain. The pain challenge involves a masseteric injection in the left or right jaw muscle of normal saline (0.15 ml bolus of 0.9% normal saline) over a 15 second period followed by continuous infusion via a closed loop infusion system for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nociceptive pain challenge
Description: The experimental, standardized, nociceptive pain challenge will induce a moderate level of sustained pain. The pain challenge involves a masseteric injection in the left or right jaw muscle of normal saline (0.15 ml bolus of 0.9% normal saline) over a 15 second period followed by continuous infusion via a closed loop infusion system for 20 minutes.
Study: NCT06375161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR-T cells
Description: Before cell infusion, Investigator may decide, based on necessity, whether to administer prophylactic medication, which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others.~Subjects are allowed to receive adequate supportive care after anti-CD19-CAR-T cell infusion, including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesics, etc.
Study: NCT05786430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib/Pemetrexed/Carboplatin
Description: Combination of lazertinib 240 mg (80 mg, 3 tablets) and pemed-S + carboplatin. Once a day lazertinib 240 mg pemed-S: 500mg/m2 q3w carboplatin: AUC5 q3w (only administered up to 4 cycles)
Study: NCT06025032

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HG205
Description: The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
Study: NCT05537831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The ultrasound will be used to assist with the delivery of a hematoma block in patients with distal forearm fractures.
Study: NCT04850794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support Tool
Description: The decision support tool is an observational checklist with recommendations for specific specialist referrals based on what the provider observed during the feeding evaluation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support Tool
Description: The decision support tool is an observational checklist with recommendations for specific specialist referrals based on what the provider observed during the feeding evaluation.
Study: NCT04870684

Intervention type: OTHER
Intervention: thromboelastometry test
Description: This study does not modify the usual care of the patient. Only 5 citrated tubes (maximum 15 mL of blood) are collected in addition to the initial emergency department sample (routine care). The patient's care follows the classic thrombolysis alert pathway. There is no additional complementary examination or additional neurological evaluation. Clot formation kinetics will be evaluated by thromboelastometry to determine the predictive parameters of revascularization. Clot formation and lysis parameters as well as revascularization according to thrombo-inflammation processes will be studied.
Study: NCT05034120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Administer a single dose of XZP-3621 tablet after a low-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9) : Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after on an empty stomach in a single dose on Day19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9) : Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day19.
Study: NCT04754308

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Spirometry
Description: The method of examination, Spirometry, is non-invasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
Study: NCT04961658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM00220
Description: Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM00220
Description: Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM00220
Description: Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM00220
Description: Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion
Study: NCT05025046

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroscan
Description: To evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nudules with abnormal ultrasound features.
Study: NCT05812287

Intervention type: OTHER
Intervention: Detection of biological samples based on multi-omics analysis
Description: In this study, we combined microbiological (16SrRNA) and metabolomic mass spectrometry to study the changes in microbial populations and metabolic profiles of various samples such as feces, serum, and saliva, and screen key differential markers.

Intervention type: OTHER
Intervention: Detection of biological samples based on multi-omics analysis
Description: In this study, we combined microbiological (16SrRNA) and metabolomic mass spectrometry to study the changes in microbial populations and metabolic profiles of various samples such as feces, serum, and saliva, and screen key differential markers.
Study: NCT05103293

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: patient-derived tumor-like cell clusters drug sensitivity test
Description: Intervention Description：Neoadjuvant therapy regimen of patients in the PTC group is guided by PTC drug sensitivity results. After operation, adjuvant targeted therapy for pCR patients is based on original treatment, adjuvant targeted therapy for non-pCR patients is based on a secondary PTC drug sensitivity results.
Study: NCT04916080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: mucolytic and anti-oxidant. Dose 10mg/Kg/ 12 hours orally
Study: NCT03966807

Intervention type: BEHAVIORAL
Intervention: Digital-based support
Description: Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.

Intervention type: BEHAVIORAL
Intervention: Traditional-based support + Nicotine replacement therapy (NRT)
Description: Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
Study: NCT05237661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moon Balance
Description: Moon Balance is a blend of 6 food ingredients
Study: NCT04951154

Intervention type: OTHER
Intervention: Bronchoscopic Biopsy
Description: Bronchoscopic biopsies will be used to evaluate biomarkers of tumor biology and immunology.

Intervention type: OTHER
Intervention: Blood Sample
Description: Blood samples will be obtained to measure circulating biomarkers.
Study: NCT05071196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated Vegan Diet
Description: Vegan boxed meal kits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omnivorous Diet
Description: Non-vegan boxed meal kits
Study: NCT06056167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degludec insulin
Description: Enrolled patients will be initiated on regular insulin sliding scale (ISS) every 6 hours, administrated subcutaneously at 0600, 1200, 1800 and 2400 in patients who are nil per os and on intravenous fluid or parenteral nutrition or continuous tube feeding, according to King Faisal Specialist Hospital \& Research Center (KFSH\&RC) protocol.~Patients with two capillary point of care glucose levels of \> 10 mmol/L (180 mg/dl) will be initiated on insulin degludec at dose of 0.2 units/ kg.~Dose adjustments will be carried out on daily basis based on blood glucose levels following a written protocol.
Study: NCT03752918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: A single dose of 1.5mg/kg will be administered once orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niacin
Description: A single dose of 250mg will be administered once orally.
Study: NCT05232994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg
Description: Combination 2 g of oral extended release metformin, Esomeprazole 20mg daily until delivery.
Study: NCT05352568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Computer-Based Cognitive Training from BrainHQ (Posit Science)
Study: NCT05532943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells
Description: UMSC01 cells will be IV infusion followed by IT infusion with 12 months of follow up after treatment.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Normal saline will be IV infusion followed by sham-IT infusion with 12 months of follow up after treatment.
Study: NCT04778423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avatar Therapy
Description: In the first session (assessment), participants will create a computerised representation of the eating disorder voice (avatar) on a computer. They will be able to manipulate the facial and voice characteristics of the avatar and will be asked to provide examples of the critical eating disorder comments most often spoken by the avatar. In the following sessions (6-8 therapy sessions), participants will interact with the avatar displayed on the computer screen for 5-10 minutes.The main goal during the interaction with the avatar is for participants to stand up to the critical comments made by the avatar and build a sense of power, control and self-awareness in the context of the eating disorder voice. The sessions will be conducted remotely, using a personal laptop or computer. This will provide patients with the opportunity to practise answering back to the eating disorder voice during a meal, a time at which the eating disorder voice is loudest.
Study: NCT04819607

Intervention type: OTHER
Intervention: model of care
Description: Multidisciplinary model of care for BMFS patients.
Study: NCT05695521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CK0803
Description: CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Excipient
Description: Excipient
Study: NCT04911296

Intervention type: OTHER
Group type: OTHER
Intervention: Mock-RP
Description: Standard 000 capsule filled with potato starch, enteric-coated with colorant and lubricious coating.
Study: NCT05354596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STRICT LUNG
Description: Stereotactic body radiation therapy: Centrally located tumors are treated on standard-linacs with daily CBCT image-guidance and plan adaptation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STAR LUNG
Description: Stereotactic body radiation therapy: Ultra-centrally tumors are treated on MR-linacs with daily MR-guided plan-adaptation.
Study: NCT04383210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seribantumab
Description: Anti-HER3 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seribantumab
Description: Anti-HER3 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seribantumab
Description: Anti-HER3 monoclonal antibody
Study: NCT06086717

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: One Y-shaped strap with 25% stretch was applied from the mid third of the thigh over the rectus femoris, then its ends directed toward the tibial tuberosity by enwrapping the patella from lateral and medial sides. In 45° knee flexion one eye strap from medial to lateral was applied through the collateral medial and lateral ligaments.~For the facilitation of VMO 1 eye strap with 25% stretch from medial aspect of thigh to quadriceps tendon. Lastly, 1 eye strap with 25% stretch from tibial tuberosity to lateral aspect of thigh for inhibition of Vastus lateralis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Following a protocol according to patient and limb, the tensor fasciae latae, hip adductors, hamstrings, quadriceps, gastrocnemius, and popliteus muscles were properly examined in each subject. These muscles are frequently involved in muscle-related knee pain.~Patients with knee OA who had at least one active MTrP that produced pain were recruited. Patients received a total of 8 DN sessions (2 sessions per week for 4 weeks) at all MTrPs of the lower limbs using the fast-in and fast-out technique (the needle was moved up and down within the muscle).
Study: NCT05154786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization and endurance training
Description: The early mobilization and endurance training will be conducted with grading exercise level. In the course of endurance training. After achieving patient's active participation in sitting on the bed, the goal will be to train for at least 20 min. If this is accomplished, exercise level and training period increased until a maximum of 7 on modified RPE. If these are well-tolerated and no contraindications as per medical prescription exist, the treatment will be further advanced to mobilizing participants to the bedside. After being able to sit for at least 10 min on the side of the bed, regardless of whether support is needed, participants will be moved into a chair with an individually adapted transfer according to the individual's resources.While sitting, functional tasks and activities of daily living will be performed and gradually increased to standing and walking exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The weaning protocols, bed exercise, positioning, respiratory therapy, and early mobilization.
Study: NCT05949112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft bristle toothbrush
Description: manual toothbrushes
Study: NCT05690802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron hydrochloride capsules
Description: This protocol only stipulates Palonosetron capsule containing hydrochloric acid protocol, and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage.
Study: NCT06239675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be delivered anodal for 20 minutes at an intensity between 1mA and 2mA for 15 sessions.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CIMT
Description: CIMT will be administered for two hours a day, five days a week, and three weeks in a row.
Study: NCT05949112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical toothbrush
Description: sonic toothbrush
Study: NCT06239675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIMT
Description: CIMT will be administered for two hours a day, five days a week, and three weeks in a row.
Study: NCT06347406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction combined with physiotherapy and education
Description: Blood flow restriction Physiotherapy exercises Education

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood flow restriction combined with physiotherapy and education
Description: Blood flow restriction Physiotherapy exercises Education
Study: NCT05660239

Intervention type: OTHER
Group type: OTHER
Intervention: Community Intervention
Description: To evaluate the impact of a community intervention in reducing epilepsy stigma in adolescents.

Intervention type: OTHER
Group type: OTHER
Intervention: Community Intervention
Description: To evaluate the impact of a community intervention in reducing epilepsy stigma in adolescents.
Study: NCT04923074

Intervention type: OTHER
Intervention: diffusion tensor imaging(DTI) evaluation
Description: DTI is a new kind of MRI technique to evaluate peripheral neuropathy
Study: NCT06164067

Intervention type: OTHER
Intervention: abortus within 24 hours or 24-48 hours
Description: second trimester medical termination

Intervention type: OTHER
Intervention: abortus within 24 hours or 24-48 hours
Description: second trimester medical termination
Study: NCT05682157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paula Method of muscle exercises
Description: 12 weekly sessions of Paula Method of exercise
Study: NCT06159322

Intervention type: DRUG
Intervention: Olanzapine
Description: Antipsychotic medication

Intervention type: DRUG
Intervention: Clozapine
Description: Antipsychotic medication
Study: NCT06119672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Blend Oral capsules
Description: probtiotic bend oral tablets from biovia will be adminestrated containing 4 strains ( twice daily) in addition to topical clobetasol application twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids for Local Oral Treatment
Description: topical clobetasol probionate in orabase application 4 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids for Local Oral Treatment
Description: topical clobetasol probionate in orabase application 4 times daily